Using the GORE® Septal Occluder (GSO) in Challenging Patent Foramen Ovale (PFO) Anatomies

被引:9
作者
Geis, Nicolas A. [1 ]
Pleger, Sven T. [1 ]
Katus, Hugo A. [1 ]
Hardt, Stefan E. [1 ,2 ]
机构
[1] Heidelberg Univ, Dept Internal Med 3, D-69120 Heidelberg, Germany
[2] Ctr Cardiac & Circulatory Dis, Bruchsal, Germany
关键词
TRANSCATHETER CLOSURE; PERCUTANEOUS CLOSURE; MEDICAL THERAPY; CRYPTOGENIC STROKE; CLINICAL-EXPERIENCE; AMPLATZER; MORPHOLOGY; DEVICES;
D O I
10.1111/joic.12181
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesWe assessed efficacy and safety of the Gore((R)) Septal Occluder (GSO) for patent foramen ovale (PFO) closure focusing on patients with challenging septal anatomies. BackgroundIn times of controversial discussion whether percutaneous PFO closure is superior to medical therapy for the prevention of recurrent embolic events after cryptogenic stroke, patient selection should mainly focus on individuals with an increased likelihood that the ischaemic event is related to the PFO. In this context, specific septal anatomiessuch as the presence of an atrial septal aneurysm as well as long PFO tunnel anatomyhave been associated with a higher rate of cerebrovascular accidents. MethodsThe GSO was used for PFO closure in 41 patients presenting with either atrial septal aneurysm (ASA; 27/41; 65.9%) or long PFO tunnel (>10mm; 32/41; 78%). Seven of these patients even presented with a tunnel length 20mm (7/41; 17.1%). Eighteen patients had both, long-tunnel anatomy and ASA (18/41; 43.9%). ResultsThe GSO was successfully implanted in all cases. No procedural complications occurred and all patients were discharged the day after the procedure. Short-term follow-up, including TEE examination, in all patients was performed 37.69.0 days after the procedure. Mid-term follow-up was performed after 192.7 +/- 45.3 days. Later complications occurred in 7.3% (2 new onset atrial fibrillation, 1 device thrombus). Only 3 patients (7.3%) had more than trace residual shunts at 6-weeks follow-up. At 6-months follow-up, the complete closure rate was 95.1% (39/41). ConclusionsThe Gore((R)) Septal Occluder is an efficient device for patent foramen ovale closure in challenging anatomies, including long-tunnel PFOs and atrial septal aneurysms.
引用
收藏
页码:190 / 197
页数:8
相关论文
共 29 条
[1]  
Butera G, 2012, CONGENITAL CARDIOLOG, V10, P1
[2]   Transcatheter PFO Closure With GORE® Septal Occluder: Early and Mid-Term Clinical Results [J].
Butera, Gianfranco ;
Saracino, Antonio ;
Danna, Paolo ;
Sganzerla, Paolo ;
Chessa, Massimo ;
Carminati, Mario .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2013, 82 (06) :944-949
[3]   Updating the evidence on patent foramen ovale closure versus medical therapy in patients with cryptogenic stroke: a systematic review and comprehensive meta-analysis of 2,303 patients from three randomised trials and 2,231 patients from 11 observational studies [J].
Capodanno, Davide ;
Milazzo, Giovanni ;
Vitale, Luca ;
Di Stefano, Daniele ;
Di Salvo, Marilena ;
Grasso, Carmelo ;
Tamburino, Corrado .
EUROINTERVENTION, 2014, 9 (11) :1342-1349
[4]   Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke [J].
Carroll, John D. ;
Saver, Jeffrey L. ;
Thaler, David E. ;
Smalling, Richard W. ;
Berry, Scott ;
MacDonald, Lee A. ;
Marks, David S. ;
Tirschwell, David L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (12) :1092-1100
[5]  
Chiam PTL, 2008, J INVASIVE CARDIOL, V20, P665
[6]   A Novel System for Transcatheter Closure of Patent Foramen Ovale: Clinical and Echocardiographic Outcome Comparison With Other Contemporary Devices [J].
Darsaklis, Konstadina ;
Freixa, Xavier ;
Asgar, Anita ;
Ibrahim, Reda ;
Basmadjian, Arsene ;
DeGuise, Pierre ;
Garceau, Patrick .
CANADIAN JOURNAL OF CARDIOLOGY, 2014, 30 (06) :639-646
[7]   Initial clinical experience with the GORE septal occluder for the treatment of atrial septal defects and patent foramen ovale [J].
Freixa, Xavier ;
Ibrahim, Reda ;
Chan, Jason ;
Garceau, Patrick ;
Dore, Annie ;
Marcotte, Francois ;
Mercier, Lise-Andree ;
Mongeon, Francois-Pierre ;
Basmadjian, Arsene ;
Khairy, Paul ;
Asgar, Anita W. .
EUROINTERVENTION, 2013, 9 (05) :629-635
[8]   Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale [J].
Furlan, Anthony J. ;
Reisman, Mark ;
Massaro, Joseph ;
Mauri, Laura ;
Adams, Harold ;
Albers, Gregory W. ;
Felberg, Robert ;
Herrmann, Howard ;
Kar, Saibal ;
Landzberg, Michael ;
Raizner, Albert ;
Wechsler, Lawrence .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (11) :991-999
[9]   Morphology of the Patent Foramen Ovale in Asymptomatic Versus Symptomatic (Stroke or Transient Ischemic Attack) Patients [J].
Goel, Sachin S. ;
Tuzcu, E. Murat ;
Shishehbor, Mehdi H. ;
de Oliveira, Eduardo F. ;
Borek, Przernyslaw P. ;
Krasuski, Richard A. ;
Rodriguez, Leonardo L. ;
Kapadia, Sarnir R. .
AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (01) :124-129
[10]   Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale [J].
Hornung, Marius ;
Bertog, Stefan C. ;
Franke, Jennifer ;
Id, Dani ;
Taaffe, Margaret ;
Wunderlich, Nina ;
Vaskelyte, Laura ;
Hofmann, Ilona ;
Sievert, Horst .
EUROPEAN HEART JOURNAL, 2013, 34 (43) :3362-3369